Prime Medicine, Inc. Other Noncash Income (Expense)
Prime Medicine, Inc. (PRME) reported Other Noncash Income (Expense) of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2023-05-11
- Prime Medicine, Inc. other noncash income (expense) for the quarter ending 2023-03-31 was $0.00.
- Prime Medicine, Inc. other noncash income (expense) for the quarter ending 2022-03-31 was $0.00.
- Prime Medicine, Inc. other noncash income (expense) for fiscal 2022 was $0.00.
- Prime Medicine, Inc. other noncash income (expense) for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Prime Medicine, Inc. other noncash income (expense) for fiscal 2020 was $126.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 12 month |
|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2020-12-31 | $126.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |